Lupin Limited has informed the Exchange regarding a press release dated September 30, 2025, titled "Lupin Receives Approval from U.S. FDA for Rivaroxaban for Oral Suspension ".
Press Release Sep 30 2025
Filed with NSE ·
6ix hasn’t read this filing yet.
Earlier from Lupin
- Lupin Strengthens its Global Specialty Ophthalmology Business with Acquisition of VISUfarma from GHO Capital
- Press Release Sep 24 2025
- Press Release Sep 17 2025
- Lupin Receives U.S. FDA Approval for Risperidone Long-Acting Injectable, with 180-Day CGT Exclusivity, the First Product from its Nanomi's Long-Acting Injectable Platform
- Press Release Sep 03 2025
Later from Lupin
- Press Release Oct 01 2025
- Press Release Oct 03 2025
- Lupin Announces Plans to Build a New State-of-the-Art Manufacturing Facility in Coral Springs, Florida Extending its Long-Standing Commitment to America's Patients and Healthcare System
- Press Release Oct 08 2025
- Lupin Unveils Strategic Partnership Program to Expand Reach of its Long-Acting Injectable Platform
Follow Lupin into a list and get an email when it puts out news.
Follow Lupin